Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhejiang Tianyu Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Vardenafil Hydrochloride Tablets issued by the National Medical Products Administration. The specification is 10 mg, indicated for the treatment of male erectile dysfunction. The drug registration classification is chemical drug category 4, and the approval number is valid until August 3, 2031. According to data from Menet, the drug's sales in domestic sample hospitals and urban brick-and-mortar pharmacies in 2025 were approximately 14 million yuan. As of July 31, 2026, the company's cumulative R&D investment in this product was approximately 6.63 million yuan. The company stated that this approval will further enrich its formulation portfolio and is expected to increase formulation business revenue, but drug sales are affected by factors such as changes in the market environment, and profitability is uncertain.
Zhejiang Tianyu Pharmaceutical Co LtdSubsidiary obtained drug registration certificate for Vardenafil Hydrochloride Tablets, a new product approval that enriches portfolio and may boost revenue.
